Camptothecins in Cancer Therapy

Clinical interest in the camptothecins continues to expand even though this class of topoisomerase I inhibitors has been studied for almost 50 years, and two early generation members of the family have gained FDA approval. In Camptothecins in Cancer Therapy, leading clinicians and researchers critic...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor Corporativo: SpringerLink (Online service)
Otros Autores: Adams, Val R. (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Totowa, NJ : Humana Press : Imprint: Humana, 2005.
Edición:1st ed. 2005.
Colección:Cancer Drug Discovery and Development,
Temas:
Oncology.
Acceso en línea:Texto Completo
Tabla de Contenidos:
  • Biochemistry, Pharmacology, and Chemistry
  • Mechanism of Action of Topoisomerase 1 Poisons
  • Crystallographic Insight Into the Mechanism of Drug-Induced Topoisomerase I DNA Damage
  • Inhibitors of Topoisomerase I Function
  • Cytotoxic Mechanisms of Topoisomerase 1 Inhibitors
  • Biochemical and Genetic Analyses of DNA Topoisomerase 1-Mediated DNA Damage
  • Preclinical Models for Evaluating Topoisomerase I-Targeted Drugs
  • Mechanisms of Resistance to Camptothecins
  • Recent Advances in Camptothecin Drug Design and Delivery Strategies
  • Clinical Perspectives
  • Clinical Experience With 9-Aminocamptothecin
  • Clinical Studies of Rubitecan (9-Nitro 20(S) Camptothecin)
  • Irinotecan
  • Clinical Experience With Topotecan
  • The Clinical Development of Lurtotecan
  • Preclinical and Clinical Development of Exatecan (DX-951f)
  • Camptothecins in the Treatment of Primary Brain Tumors
  • Camptothecins in the Treatment of Lung Cancer
  • Use of Camptothecins in the Treatment of Leukemia and Related Disorders.

Ejemplares similares